Start here if you're new
what it is
It tries to make medicines for muscle disease, cancer, and scarring problems.
how it gets paid
Last year Scholar Rock Hold made $0 in revenue.
what just happened
Scholar Rock posted $0 revenue and a -$2.54 EPS loss in the latest quarter.
At a glance
B+ balance sheet — decent shape, but not bulletproof
65/100 earnings predictability — reasonably predictable
-$3.29 fy2025 eps est
$2B fy2026 rev est
1.4 beta
xvary composite: 52/100 — below average
What they do
It tries to make medicines for muscle disease, cancer, and scarring problems.
Apitegromab is in Phase 2, and SRK-181 is in Phase 1. Phase 2 → mid-stage human testing → so what: you are paying for proof, not sales. The company has 196 employees and a Gilead collaboration, so every data update can hit your stock hard.
How they make money
$0
annual revenue
The products that matter
lead SMA drug candidate
Apitegromab
$0 revenue today · carries the ~$5B story
it is the asset the market cares about. with $0 in trailing revenue and a ~$5B market cap, you are effectively underwriting apitegromab's path to approval and launch.
single asset
preclinical research platform
TGF-beta inhibitor platform
pre-revenue · no near-term offset
the platform may matter later, but it does not support today's valuation on its own. Right now, the market is paying for one program, not a diversified pipeline.
option value
capital runway and execution
balance sheet
B+ grade · $100M long-term debt
for a company with no product sales, financing is part of the product. the B+ balance sheet buys time, but not immunity from dilution, debt pressure, or market mood swings.
fund the science
Key numbers
$5.0B
market cap
You are paying $5.0B for a company with $0 in annual sales.
$0
annual revenue
Zero sales means the stock trades on pipeline hope, not current cash flow.
-$3.29
fy25 eps
Losses of $3.29 a share mean the company spends before it earns.
1.4
beta
A beta of 1.4 means the stock moves about 40% more than the market.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $100M (2% of capital)
B+ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for SRRK right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Scholar Rock posted $0 revenue and a -$2.54 EPS loss in the latest quarter.
The quarter still had no sales. The business is spending on trials, not selling drugs.
$0.0B
revenue
-$2.54
eps
n/a
n/a
cash burn
The $0 revenue number matters because the whole valuation rests on future approvals, not current demand.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is apitegromab failing to reach a clean commercial path. with $0 in trailing revenue and a ~$5B valuation, this story has very little room for a serious clinical, regulatory, or launch stumble.
high
single-asset concentration
apitegromab is the investment case. if the lead program disappoints, there is no established revenue base to cushion the blow and no broad commercial portfolio behind it.
this risk sits against $0 in trailing revenue and a ~$5B equity value.
high
commercial expectations are already doing a lot of work
the page carries a $2B fy2026 revenue estimate despite no trailing revenue today. that gap tells you how much of the stock price rests on execution that has not happened yet.
if launch timing slips or uptake disappoints, the valuation framework resets fast.
med
leadership transition at the worst possible time
a new CEO took over in april 2025. that's manageable in a diversified company. in a single-asset biotech approaching a make-or-break stretch, it adds execution risk.
the science matters most, but management still has to get manufacturing, messaging, and market prep right.
med
share price volatility is part of the package
price stability is 5 / 100 and beta is 1.4. in plain english, this stock is built for hard reactions to new information, not quiet compounding.
even good news can come with violent moves if expectations were already crowded.
you are paying roughly $5B for a company with no trailing revenue because the market believes one program can become a real business. if that belief weakens, the downside can be abrupt.
source: institutional data · regulatory filings · risk analysis
Pay attention to
valuation gap
$2B forecast versus $0 trailing revenue
that contrast is the whole page in one line. if management starts narrowing the gap with real commercialization progress, the thesis gets sturdier. if not, the stock is living on future tense.
next print
Q1 2026 earnings and cash-burn commentary
HC Wainwright estimates Q1 EPS at -$0.90. the reported loss matters less than management's read on runway, timing, and launch readiness.
execution risk
manufacturing and regulatory clarity for apitegromab
Truist expects manufacturing site issues and broader pipeline clarity to move in 2026. for SRRK, operational de-risking is not a side issue. it's the issue.
leadership
whether the new CEO can turn a clinical story into a launch story
David Hallal took over in april 2025. watch whether communication gets sharper, milestones get cleaner, and the company starts sounding like it can actually commercialize what it is building.
Analyst rankings
earnings predictability
65 / 100
in human-speak, analysts have a workable model here, but the model is only as stable as the next trial, timeline update, or financing shift.
beta
1.4
when the market moves, SRRK has tended to move more. add biotech event risk and you get a stock that can change character quickly.
source: institutional data
Institutional activity
institutional ownership data for SRRK is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$44
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive